Literature DB >> 18582458

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.

Masateru Taira1, Hiroe Toba, Masafumi Murakami, Ikumi Iga, Ryoko Serizawa, Shoko Murata, Miyuki Kobara, Tetsuo Nakata.   

Abstract

Aldosterone itself has been reported to participate in mediating renal injury, and it was confirmed that the aldosterone synthase CYP11B2 gene, protein, and aldosterone production are locally present in the kidney. To test the hypothesis that a mineralocorticoid receptor antagonist might ameliorate diabetic nephropathy and the inhibition of renal CYP11B2 expression might be associated with these renoprotective effects, spironolactone (50 mg/kg/day) was administered by gavage to uninephrectomized diabetic rats for 3 weeks. Streptozotocin (55 mg/kg, i.v.) significantly increased urinary protein excretion and collagen deposition in glomerular and tubulointerstitial areas in the kidney, which were attenuated by spironolactone treatment. RT-PCR and Western blot analysis revealed that the expression of mRNA for collagen I/IV, transforming growth factor-beta, NADPH oxidase and mineralocorticoid receptor and the mineralocorticoid receptor protein in the kidney was enhanced in the uninephrectomized diabetic rat kidney and that the overexpression of these molecules was suppressed by spironolactone. Renal angiotensin converting enzyme was activated and overexpressed in diabetic rats, and spironolactone inhibited these changes. We demonstrated that spironolactone prevented the streptozotocin-induced increase in the renal CYP11B2 mRNA content. Controlling blood glucose level with insulin also attenuated the renal expression of mRNA for CYP11B2. On the other hand, the treatment of spironolactone in the present study did not affect blood glucose level or blood pressure in uninephrectomized streptozotocin-induced diabetic rats. These results suggest that spironolactone exerted renoprotective effects in uninephrectomized streptozotocin-induced diabetic rats and inhibited local renin-angiotensin-aldosterone system, such as the ACE expression and the hyperglycemia-induced overexpression of CYP11B2, in the kidney.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582458     DOI: 10.1016/j.ejphar.2008.06.019

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  29 in total

1.  Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-06-24       Impact factor: 2.778

Review 2.  Targeting NOX enzymes in pulmonary fibrosis.

Authors:  Louise Hecker; Jeff Cheng; Victor J Thannickal
Journal:  Cell Mol Life Sci       Date:  2012-05-23       Impact factor: 9.261

Review 3.  NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-10-24       Impact factor: 3.017

Review 4.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 5.  NADPH oxidases in lung health and disease.

Authors:  Karen Bernard; Louise Hecker; Tracy R Luckhardt; Guangjie Cheng; Victor J Thannickal
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

Review 6.  Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?

Authors:  Yves Gorin; Karen Block
Journal:  Free Radic Biol Med       Date:  2013-03-23       Impact factor: 7.376

7.  Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

Authors:  Akira Nishiyama; Hiroyuki Kobori; Yoshio Konishi; Takashi Morikawa; Isseki Maeda; Michiaki Okumura; Masatsugu Kishida; Masahiro Hamada; Yukiko Nagai; Toshitaka Nakagawa; Naro Ohashi; Daisuke Nakano; Hirofumi Hitomi; Masahito Imanishi
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

Review 8.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

9.  An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

Authors:  Guangyu Zhou; Ulrika Johansson; Xiao-Rong Peng; Krister Bamberg; Yufeng Huang
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

Review 10.  Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Authors:  Elaine Ku; Vito M Campese
Journal:  Pediatr Nephrol       Date:  2009-04-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.